Ann Surg Oncol

1. JU T, Zhang J, Tsai J
   Editorial Comment: The Clinical Imperative of Race Disaggregation in Asian American Breast Cancer.
   Ann Surg Oncol. 2026 Sep 24. doi: 10.1245/s10434-026-20607.
   

   >> Share

   
   
2. DE BRUIJN A, de Jonge C, Vriens BEP, van Kats MACE, et al
   A Decade of Change: Systemic Treatment Patterns in Clinically Small HER2-Positive Node-Negative Breast Cancer in the Netherlands: A Population-Based Study.
   Ann Surg Oncol. 2026 Sep 23. doi: 10.1245/s10434-026-20569.
   

   >> Share

   
   
3. XIA LY, Cao XC, Hu QL
   ASO Visual Abstract: Discordance Between Breast and Axillary Responses After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Implications for Surgical De-escalation.
   Ann Surg Oncol. 2026 Sep 23. doi: 10.1245/s10434-026-20618.
   

   >> Share

   
   
4. STRAUSS E, Hyman J, Paluch-Shimon S, Breuer S, et al
   ASO Visual Abstract: Fertility Preservation Pathways for Young Women with Breast Cancer: A Single-Center Analysis in a Publicly Funded System.
   Ann Surg Oncol. 2026 Sep 23. doi: 10.1245/s10434-026-20553.
   

   >> Share

   
   

   
   BMC Cancer

5. AYDIN O, Dogan HGY, Sonusen SD, Erciyestepe M, et al
   The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience.
   BMC Cancer. 2026;26:1140.
   

   >> Share

   
   

   
   Br J Cancer

6. ALBERS FE, Swain CT, Dashti SG, Rinaldi S, et al
   Inflammatory biomarkers and risk of postmenopausal oestrogen receptor-positive breast cancer: a case-cohort analysis.
   Br J Cancer. 2026 Sep 19. doi: 10.1038/s41416-026-03624.
   

   >> Share

   
   

   
   Breast Cancer

7. OGO E, Arimura T, Ogino T, Toh U, et al
   Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.
   Breast Cancer. 2026 Sep 19. doi: 10.1007/s12282-026-01916.
   

   >> Share

   
   
8. DEMIR N, Gokmen I, Garbioglu DB, Tastekin E, et al
   Triggering receptors expressed on myeloid cells (TREM-1) and TREM-2 as predictors of pathological complete response to neoadjuvant therapy in triple-negative breast cancer.
   Breast Cancer. 2026 Sep 21. doi: 10.1007/s12282-026-01918.
   

   >> Share

   
   

   
   Breast Cancer (Dove Med Press)

9. WANG T, Yan L, Jiang J, He J, et al
   RNA-Binding Protein CSTF2 Drives Immune Evasion and Malignant Progression in Breast Cancer by Degrading THSD1 mRNA.
   Breast Cancer (Dove Med Press). 2026;18:620942.
   

   >> Share

   
   
10. AIYAPPA-MAUDSLEY R, Hughes TA
    AOH1996, an Inhibitor of PCNA, Sensitises Breast Cancer Cells to Cytotoxic Chemotherapy.
    Breast Cancer (Dove Med Press). 2026;18:636967.
    

    >> Share

    
    
11. MALLAVARAPU KM, Reddy B R, Sp S, Goyal P, et al
    Development of a Consensus-Based Risk Stratification Algorithm for HR+/HER2- Early Breast Cancer to Guide Adjuvant CDK4/6i Therapy: Outcomes from a Multidisciplinary Workshop in India.
    Breast Cancer (Dove Med Press). 2026;18:620643.
    

    >> Share

    
    

    
    Breast Cancer Res

12. MU J, Zhang M, Chen Q, Liu W, et al
    Unveiling CCL5: the master regulator of breast cancer progression and immune evasion.
    Breast Cancer Res. 2026;28:159.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

13. HLAVIN C, Balogun Z, Lavage DR, Cowher MS, et al
    Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2026;219:18.
    

    >> Share

    
    
14. O'SHAUGHNESSY J, Rehnquist MK, Sadetsky N, Verret W, et al
    A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy.
    Breast Cancer Res Treat. 2026;219:19.
    

    >> Share

    
    
15. VENARDI A, Shojaeian F, Diaz S, Schuster CR, et al
    Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis.
    Breast Cancer Res Treat. 2026;219:21.
    

    >> Share

    
    
16. HUYNH PY, Tran BV, Ngo VT, Tran TT, et al
    Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2026;219:20.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

17. ONDER T, Ates O, Yilmaz ME, Duran AO, et al
    Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.
    Cancer Chemother Pharmacol. 2026;96:110.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

18. LU Q, Wong-Meli CCY, Valdez-Dadia A, Shin-Cho LJ, et al
    Disparities in Quality of Life between Asian American and Non-Hispanic White American Breast Cancer Survivors.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Cancer Lett

19. LI Y, Yuan B, Liu J, Wang X, et al
    PRMT1 and YBX1 Cooperatively Transcriptionally Activate GPX4 to Inhibit Ferroptosis and Promote Breast Cancer Progression.
    Cancer Lett. 2026 Sep 22:218849. doi: 10.1016/j.canlet.2026.218849.
    

    >> Share

    
    

    
    Clin Breast Cancer

20. YANG EJ, Chung SH, Cho JH, Suh MR, et al
    From Surveillance to Intervention in Breast Cancer-Related Lymphedema: Clinical Thresholds, Longitudinal Monitoring, and Actionable Care Pathways.
    Clin Breast Cancer. 2026;26:147-155.
    

    >> Share

    
    

    
    Clin Cancer Res

21. TUTT A, Nowecki Z, Szoszkiewicz R, Im SA, et al
    Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.
    Clin Cancer Res. 2026 Sep 21. doi: 10.1158/1078-0432.CCR-26-1066.
    

    >> Share

    
    

    
    Eur J Cancer

22. GIELEN RCAM, Poncet C, van 't Veer LJ, Rubio IT, et al
    70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.
    Eur J Cancer. 2026;247:117044.
    

    >> Share

    
    
23. BERNARD-TESSIER A, Spanggaard I, Utriainen T, Tanner M, et al
    Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.
    Eur J Cancer. 2026;248:117041.
    

    >> Share

    
    

    
    Eur J Surg Oncol

24. VAN DER VEEN JE, Visser E, Hendrickx AA, Kuthe SW, et al
    Impairment of upper extremity function following mastectomy and lumpectomy.
    Eur J Surg Oncol. 2026;52:112063.
    

    >> Share

    
    
25. JUNG JJ, Paggao JNK, Han NH, Kang E, et al
    Revisiting OPTIMIST trial imaging criteria for pathologic complete response to neoadjuvant therapy.
    Eur J Surg Oncol. 2026;52:112030.
    

    >> Share

    
    
26. ZENG H, Nguyen L, He J, Liu N, et al
    Patient-reported longitudinal symptom patterns following breast-conserving surgery versus mastectomy with or without immediate breast reconstruction: A retrospective cohort study.
    Eur J Surg Oncol. 2026;52:112055.
    

    >> Share

    
    
27. BOUKIND A, Speller NC, Liao A, Chryssofos S, et al
    Autologous dermal flap techniques beyond inferior dermal flap coverage in implant-based breast reconstruction: A systematic review.
    Eur J Surg Oncol. 2026;52:112066.
    

    >> Share

    
    
28. SWAN RE, Turnbull A, Lucocq J, Leeper A, et al
    Survival after breast conserving surgery in patients with multiple ipsilateral breast cancers.
    Eur J Surg Oncol. 2026;52:112056.
    

    >> Share

    
    
29. LEE CH, Kim K, Byun D, Nam SJ, et al
    Axillary nodal burden and preoperative predictors in biopsy-proven node-positive breast cancer undergoing upfront surgery.
    Eur J Surg Oncol. 2026;52:112126.
    

    >> Share

    
    

    
    Eur Radiol

30. WANG W, Fan S
    Letter to the Editor: From detecting axillary metastasis to guiding clinically actionable axillary management in breast cancer.
    Eur Radiol. 2026 Sep 22. doi: 10.1007/s00330-026-12891.
    

    >> Share

    
    
31. HAN L, Dong Y
    Reply to the Letter to the Editor: From detecting axillary metastasis to guiding clinically actionable axillary management in breast cancer.
    Eur Radiol. 2026 Sep 22. doi: 10.1007/s00330-026-12892.
    

    >> Share

    
    
32. WANG G, Shi D, Guo Q, Wang R, et al
    Enhanced recurrence risk stratification for stages ?-? breast cancer using MRI-based structure habitat imaging.
    Eur Radiol. 2026 Sep 19. doi: 10.1007/s00330-026-12886.
    

    >> Share

    
    

    
    Histopathology

33. KOH J, Suh KJ, Park HY, Kwon HJ, et al
    Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.
    Histopathology. 2026 Sep 24. doi: 10.1111/his.70285.
    

    >> Share

    
    

    
    Int J Cancer

34. BOSETTI C, Visser O, Van Eycken L, Pettersson D, et al
    Availability of Stage Information From Cancer Registries Providing Data to the European Cancer Information System for Six Selected Cancers.
    Int J Cancer. 2026;159:2540-2551.
    

    >> Share

    
    
35. NIKOLAEVA M, Bellomo J, Gonel M, Stumpo V, et al
    Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients-A Multicenter Retrospective Cohort Study.
    Int J Cancer. 2026 Jun 18. doi: 10.1002/ijc.70611.
    

    >> Share

    
    

    
    J Biol Chem

36. QIAN T, Liu X, Bai F, He Q, et al
    USP11 deubiquitinates GATA3 to suppress the growth and metastasis of luminal-type breast cancers.
    J Biol Chem. 2026;302:113371.
    

    >> Share

    
    
37. SYEDA AK, Almasi S, Benson CJ, Kennedy BE, et al
    TRPML1 loss disrupts lysosome-mitochondria homeostasis and sensitizes MDA-MB-231 triple-negative breast cancer cells to chemotherapy.
    J Biol Chem. 2026 Sep 22:113596. doi: 10.1016/j.jbc.2026.113596.
    

    >> Share

    
    
38. YANG Y, Wang B
    Monitoring Py8119 breast cancer cell proliferation in direct cocultures with osteoblasts and osteoclasts.
    J Biol Chem. 2026 Sep 23:113597. doi: 10.1016/j.jbc.2026.113597.
    

    >> Share

    
    

    
    J Natl Cancer Inst

39. CESPEDES FELICIANO EM, Fuller SE, Nugent JR, Cao A, et al
    Lifestyle and chemotherapy shape functional aging trajectories in older breast cancer survivors and matched comparators.
    J Natl Cancer Inst. 2026 Sep 23:djag292. doi: 10.1093.
    

    >> Share

    
    

    
    J Surg Oncol

40. ROUMANI H, Aydas O
    Breast-Conserving Therapy Versus Mastectomy in Estrogen Receptor-Positive Breast Cancer: A PAM50-Adjusted Survival Analysis.
    J Surg Oncol. 2026 Sep 25. doi: 10.1002/jso.70404.
    

    >> Share

    
    

    
    Oncogene

41. FERNANDEZ-CALERO T, Metivier R, Percevault F, Clusan L, et al
    Synonymous codon usage shapes ERalpha function through specialized translational programs during breast cancer progression.
    Oncogene. 2026 Sep 24. doi: 10.1038/s41388-026-03991.
    

    >> Share

    
    
42. GUO Q, Chen X, Wu L, Ren C, et al
    AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies.
    Oncogene. 2026;45:4132-4148.
    

    >> Share

    
    

    
    Oncol Rep

43. LUO Q, Wei C, Li X, Li J, et al
    [Expression of Concern] MicroRNA?195?5p is a potential diagnostic and therapeutic target for breast cancer.
    Oncol Rep. 2026;56:194.
    

    >> Share

    
    

    
    Oncology

44. SU M, Patel D, Syed S, Delgado-Ramos G, et al
    Impact of Clinicopathologic Factors on Breast Cancer Diagnosed in Pregnancy.
    Oncology. 2026 Sep 22:1. doi: 10.1159.
    

    >> Share

    
    

    
    PLoS Biol

45. NAZEMI M, Yanes B, Vancauwenberghe E, Oyelade I, et al
    Collagen I promotes cancer cell survival via amino acid import and mTORC1/S6 activation.
    PLoS Biol. 2026;24:e3003555.
    

    >> Share

    
    

    
    PLoS One

46. GHAHROUDI MH, Ahmadinejad N, Changizi V, Ahmadi E, et al
    Development and evaluation of a deep incremental learning system for mammography image analysis.
    PLoS One. 2026;21:e0358861.
    

    >> Share

    
    
47. KLAIHMON P, Muangtate P, Thongphayong S, Saetan P, et al
    Correction: NECTIN2 depletion impairs migration and invasion in MDA-MB-231 breast cancer cells through LIMK1-associated cytoskeletal remodeling.
    PLoS One. 2026;21:e0359312.
    

    >> Share

    
    
48. AL SAFI S, Yoo TK, Kim J, Chung IY, et al
    Development and validation of a nomogram predicting pathologic complete response to neoadjuvant chemotherapy in luminal type breast cancer patients using MammaPrint(R) and clinicopathological factor.
    PLoS One. 2026;21:e0356871.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

49. WANG YK, Cockmartin L, Wagner T, Klanecek Z, et al
    Comparison of Artificial Intelligence Detection and Short-Term Breast Cancer Risk Models within and beyond Their Intended Use in Mammography Screening.
    Radiol Imaging Cancer. 2026;8:e250609.
    

    >> Share

    
    

    
    Radiother Oncol

50. VIANI GA, Hamamura AC, Arruda CV, Cardoso CE, et al
    Stereotactic ablative radiotherapy for oligometastatic breast cancer: A systematic review and meta-analysis (SABRINA).
    Radiother Oncol. 2026 Sep 20:111789. doi: 10.1016/j.radonc.2026.111789.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share